Security
KYMR · Kymera Therapeutics, Inc.
KYMRNASDAQCommon stockCurrentCIK 1815442Updated Sep 24, 2026
Name history
Kymera Therapeutics, Inc. · through Sep 8, 2026
KYMR price & chart
Loading TradingView…
NASDAQ:KYMR on TradingView ↗About the company
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
In the news
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) ↗
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) ↗
Kymera Therapeutics to Participate in Upcoming May Investor Conferences ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,742,812,000Source | 978,035,000Source | 575,759,000Source | 603,134,000Source |
| Property, Plant and Equipment, NetUSD | 43,175,000Source | 50,457,000Source | 48,134,000Source | 13,334,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 357,011,000Source | 120,256,000Source | 109,966,000Source | 68,395,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 0Source | 15,000,000Source | — |
| Assets, CurrentUSD | 871,214,000Source | 510,268,000Source | 405,317,000Source | 419,416,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 22,938,000Source | 20,577,000Source | 11,674,000Source | 9,713,000Source |
| Operating Lease, Right-of-Use AssetUSD | 42,351,000Source | 47,407,000Source | 52,945,000Source | 8,909,000Source |
| Other Assets, NoncurrentUSD | 9,114,000Source | 1,950,000Source | 2,118,000Source | 3,017,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 163,148,000Source | 142,416,000Source | 180,788,000Source | 112,983,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | — | — |
| Common Stock, Value, IssuedUSD | 8,000Source | 7,000Source | 6,000Source | 6,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,065,961,000Source | -754,610,000Source | -530,752,000Source | -383,790,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 1,800,000Source | -1,485,000Source | -552,000Source | -4,949,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,579,664,000Source | 835,619,000Source | 394,971,000Source | 490,151,000Source |
| Additional Paid in Capital, Common StockUSD | 2,643,817,000Source | 1,591,707,000Source | 926,269,000Source | 878,884,000Source |
| Liabilities and EquityUSD | 1,742,812,000Source | 978,035,000Source | 575,759,000Source | 603,134,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 83,212,000Source | 67,767,000Source | 85,691,000Source | 71,343,000Source |
| Operating Lease, Liability, CurrentUSD | 11,941,000Source | 11,594,000Source | 5,068,000Source | 2,535,000Source |
| Accounts Payable, CurrentUSD | 4,015,000Source | 5,989,000Source | 7,075,000Source | 4,335,000Source |
| Operating Lease, Liability, NoncurrentUSD | 67,034,000Source | 72,423,000Source | 77,028,000Source | 12,146,000Source |
| Other Liabilities, NoncurrentUSD | — | 0Source | 0Source | 248,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 42,274,000Source | 34,867,000Source | 33,864,000Source | 27,502,000Source |
| Deferred Tax Liabilities, NetUSD | 21,108,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -311,351,000Source | -223,858,000Source | -146,962,000Source | -154,808,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 8,313,000Source | 7,373,000Source | 3,565,000Source | 2,977,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 59,904,000Source | 55,012,000Source | 43,118,000Source | 35,480,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -1,974,000Source | -307,000Source | 2,038,000Source | 253,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -232,891,000Source | -194,501,000Source | -102,826,000Source | -153,085,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -521,061,000Source | -404,077,000Source | 139,886,000Source | 20,519,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,449,000Source | 12,838,000Source | 34,480,000Source | 2,836,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 990,713,000Source | 608,851,000Source | 4,192,000Source | 152,999,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 236,761,000Source | 10,273,000Source | 41,252,000Source | 20,433,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 312,000Source | 206,000Source | 162,000Source | 179,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 59,904,000Source | 55,012,000Source | 43,118,000Source | 35,480,000Source |
| DepreciationUSD | 8,300,000Source | 7,400,000Source | 3,600,000Source | 3,000,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | 0Source | 0Source |
| General and Administrative ExpenseUSD | 68,187,000Source | 63,534,000Source | 55,041,000Source | 43,834,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -311,351,000Source | -223,858,000Source | -146,962,000Source | -154,808,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -311,351,000Source | -223,858,000Source | -146,962,000Source | -154,808,000Source |
| Operating ExpensesUSD | 388,610,000Source | 308,707,000Source | 244,122,000Source | 208,082,000Source |
| Other Nonoperating Income (Expense)USD | 38,048,000Source | 37,777,000Source | 18,568,000Source | 6,448,000Source |
| Payments of Financing CostsUSD | 1,494,000Source | 1,576,000Source | 76,000Source | 1,130,000Source |
| Proceeds from Stock Options ExercisedUSD | 0Source | 48,740,000Source | 2,860,000Source | 3,154,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 39,211,000Source | 47,072,000Source | 78,592,000Source | 46,826,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Operating Income (Loss)USD | -349,399,000Source | -261,635,000Source | -165,530,000Source | -161,256,000Source |
| Other Nonoperating Income (Expense)USD | 38,048,000Source | 37,777,000Source | 18,568,000Source | 6,448,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -311,351,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | — | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -311,351,000Source | -223,858,000Source | -146,962,000Source | -154,808,000Source |
| Earnings Per Share, BasicUSD per share | -3.69Source | -2.98Source | -2.52Source | -2.87Source |
| Earnings Per Share, DilutedUSD per share | -3.69Source | -2.98Source | -2.52Source | -2.87Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 84,490,585Source | 75,043,991Source | 58,365,499Source | 53,933,229Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 84,490,585Source | 75,043,991Source | 58,365,499Source | 53,933,229Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 68,187,000Source | 63,534,000Source | 55,041,000Source | 43,834,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -311,351,000Source | — | — | — |
| Interest Income, OtherUSD | 38,418,000Source | 38,026,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -311,351,000Source | -223,858,000Source | -146,962,000Source | -154,808,000Source |
| Operating ExpensesUSD | 388,610,000Source | 308,707,000Source | 244,122,000Source | 208,082,000Source |
| Research and Development ExpenseUSD | 316,568,000Source | 240,248,000Source | 189,081,000Source | 164,248,000Source |
Filing attachments
kymr-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 kymr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-579 (IRF5) Phase 1 healthy vo…
Read attachment ↗d167778dex991.htm · 8-K · 2026-07-27
EX-99.1 2 d167778dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera’s industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his role after eight years of leadership at the Company Watertown, Mass. (July 27, 2026) - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical…
Read attachment ↗d62555dex991.htm · 8-K · 2026-06-25
EX-99.1 2 d62555dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026 BROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 Watertown, Mass. (June 25, 2026) - Kymera Therapeutics, Inc. (N…
Read attachment ↗kymr-ex99_1.htm · 8-K · 2026-04-30
EX-99.1 2 kymr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to KT-621 for the treatment of moderate to severe asthma, in addition to prior Fast Track designation for moderate to severe atopic dermatitis …
Read attachment ↗kymr-ex99_1.htm · 8-K · 2026-02-26
EX-99.1 2 kymr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 (IRF5) Phase 1 healthy volunteer trial with data expected in 2H26 Dr. Neil Graham, experienced biopharma lead…
Read attachment ↗d78447dex991.htm · 8-K · 2026-01-13
EX-99.1 2 d78447dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected to start in 1Q26, with data expected in 2H26 Advancing at least one new development candidate towards I…
Read attachment ↗